Prescriber Scope of Practice for ADHD in Michigan

You’ve built a psychiatric practice treating ADHD. Your patients prefer video visits. Your schedule could handle more appointments if you didn’t need to see everyone in person. One question keeps coming up: Can I legally prescribe Adderall, Ritalin, or other ADHD medications through telehealth?

The answer in 2026 is yes — with some important caveats. Federal rules currently allow it through December 31, 2026, but state laws add their own requirements, and the landscape varies significantly depending on where you practice and your professional credentials.

Here’s what you need to know to prescribe ADHD medications via telehealth legally and confidently, whether you’re a psychiatrist, PMHNP, or considering joining a telehealth platform.

The Federal Framework: Where We Stand in 2026

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 technically requires an in-person medical evaluation before prescribing any controlled substance. That would include Schedule II stimulants like Adderall and Ritalin.

But here’s what actually matters right now: The DEA and HHS have extended COVID-era telehealth flexibilities through December 31, 2026. This means you can prescribe Schedule II-V controlled substances — including ADHD medications — via telehealth without any initial in-person visit, as long as you:

• Conduct a proper clinical evaluation via live two-way audiovisual communication
• Have a legitimate medical purpose
• Follow your standard of care for ADHD diagnosis
• Maintain appropriate documentation
• Use electronic prescribing where required
• Check your state’s Prescription Drug Monitoring Program (PDMP) as mandated

This extension is the fourth such continuation, signaling that while permanent rules are pending, the DEA recognizes the value of telehealth access for psychiatric care.

What’s Coming: Permanent DEA Rules

The DEA announced three new telemedicine rules in January 2025 that will likely take effect in 2027. The key elements for ADHD prescribers:

Telemedicine Special Registration: Providers will be able to obtain a special DEA registration authorizing controlled substance prescribing via telehealth without in-person exams. This will require:

• Mandatory nationwide PDMP checks
• Strict patient identity verification during video consultations
• Compliance with additional safeguards

Established Patient Exception: If you’ve seen a patient in person at least once (or they’ve been seen by a colleague in your practice), the special telehealth rules won’t apply to ongoing treatment.

Platform Registration: Telehealth companies will need their own DEA registration, adding corporate-level oversight.

The bottom line: telehealth ADHD prescribing isn’t going away, but the compliance framework is getting more structured. Staying informed and ready to adapt will be critical.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where the Rules Actually Matter

Federal law sets the floor, but states add their own requirements — and they vary significantly. Here’s what you need to know in our six priority states.

California: Telehealth-Friendly with Growing NP Independence

The Good News: California explicitly permits telehealth exams to satisfy prescribing requirements. There’s no state-level prohibition on prescribing controlled substances via video consultation, as long as it meets the standard of care.

Key Requirements:

• Must hold a California medical license (no IMLC participation, no telehealth registration shortcut)
• Mandatory CURES (California’s PDMP) check before initial prescription and every 4 months for ongoing Schedule II therapy
• Electronic prescribing required for controlled substances

For Nurse Practitioners: California is transitioning to full practice authority through 2026. Experienced PMHNPs (those who’ve completed 3 years or 4,600 hours under physician supervision) can now practice and prescribe independently, including ADHD medications. New graduates still need supervising physician agreements initially, but this is a major shift that expands the pool of independent ADHD prescribers.

Bottom Line: California’s regulatory environment supports telehealth ADHD care. Just ensure you’re checking CURES consistently and documenting your clinical rationale thoroughly.

Texas: Physicians Only for Stimulants

The Restriction That Matters: Texas law prohibits nurse practitioners and physician assistants from prescribing Schedule II controlled substances in outpatient settings — period. The only exceptions are inpatient hospitalizations >24 hours, hospice care, or hospital emergency orders.

This means only physicians (MD/DO) can prescribe Adderall, Ritalin, or other stimulants for outpatient ADHD treatment in Texas, whether in person or via telehealth.

For Physicians:

• Telehealth prescribing of ADHD medications is permitted (the state’s telehealth law explicitly allows it for mental health conditions)
• Texas participates in the Interstate Medical Licensure Compact, so out-of-state psychiatrists can expedite licensure
• Mandatory electronic prescribing for all controlled substances
• PDMP checks required for opioids and benzos (not technically mandated for stimulants, but strongly recommended)

For PMHNPs: You can evaluate and manage ADHD patients in Texas, but a physician must sign off on any stimulant prescriptions. This requires a formal collaborative relationship.

Bottom Line: If you’re an NP considering telehealth ADHD work in Texas, you’ll need physician backup. For psychiatrists, Texas is open for business via telehealth, but the NP restriction significantly limits scalability.

Florida: Clear Psychiatric Exception

The Carve-Out: Florida law explicitly permits prescribing Schedule II controlled substances via telehealth for ‘treatment of a psychiatric disorder’ — which includes ADHD. This exception was built into Florida’s 2019 telehealth statute and remains in effect.

Unique Advantage: Florida offers an out-of-state telehealth provider registration that allows providers licensed elsewhere to treat Florida patients without obtaining a full Florida license. Requirements include:

• Active, unrestricted license in another state
• Clean disciplinary record for 5 years
• Malpractice insurance
• Registration with Florida’s E-FORCSE PDMP

This makes Florida particularly attractive for multi-state telehealth platforms.

For Nurse Practitioners: PMHNPs in Florida can prescribe ADHD medications but must work under a written protocol with a supervising psychiatrist. The good news: psychiatric nurses are exempt from Florida’s 7-day limit on Schedule II prescriptions that applies to other NPs, so you can prescribe full monthly supplies.

Key Requirements:

• Check E-FORCSE (Florida’s PDMP) before prescribing controlled substances for patients 16+
• Document that your telehealth encounter meets the ‘psychiatric disorder’ exception
• Electronic prescribing required

Bottom Line: Florida’s clear statutory framework makes compliance straightforward. The psychiatric exception and out-of-state registration option create real opportunities for telehealth expansion.

New York: Newly Aligned with Federal Rules

Recent Update: In May 2025, New York explicitly updated its regulations to allow controlled substance prescribing via telehealth ‘consistent with federal law.’ This alignment means that as long as the DEA permits telehealth prescribing (currently through end of 2026), New York permits it too.

Key Requirements:

• Mandatory I-STOP/PMP registry check every time before prescribing any Schedule II-IV controlled substance
• Electronic prescribing required for all controlled substances (in effect since 2016)
• Must hold New York medical license (no IMLC participation, no telehealth shortcuts)

For Nurse Practitioners: New York is NP-friendly. After 3,600 hours of practice experience, PMHNPs can practice independently without a written collaborative agreement and prescribe controlled substances with the same authority as physicians.

Practical Advantage: New York allows up to 90-day supplies of stimulants for ADHD if you indicate code ‘B’ (for minimal brain dysfunction/ADHD) on the prescription. This reduces refill burden for stable patients and improves treatment continuity in telehealth.

Bottom Line: New York’s 2025 regulatory update removed uncertainty. The state supports telehealth ADHD care with clear rules and good NP autonomy, but PDMP compliance is strictly enforced.

Pennsylvania: Standard of Care Applies

The Framework: Pennsylvania has no state-level prohibition on prescribing controlled substances via telehealth beyond federal requirements. The medical board’s position is that telehealth encounters can meet the standard of care for prescribing if conducted properly.

Key Requirements:

• PDMP check required before initial prescription of any controlled substance (and for each opioid/benzo prescription thereafter)
• Mandatory electronic prescribing for controlled substances
• Pennsylvania medical license required (though PA joined the IMLC in 2022, making interstate licensure easier for physicians)

For Nurse Practitioners: Pennsylvania requires collaborative agreements with physicians. The prescribing limitation that matters for ADHD: CRNPs can prescribe Schedule II controlled substances for up to 30 days only. Any continuation beyond 30 days requires physician approval.

This doesn’t mean the patient needs to see the physician — it means the NP must consult with their collaborating physician about ongoing therapy. Many practices handle this through regular case reviews.

Bottom Line: Pennsylvania’s telehealth environment is permissive, but the NP 30-day limit on stimulants requires structured physician collaboration. For psychiatrists, it’s straightforward; for PMHNPs, you need a collaborative practice agreement that accounts for the monthly physician review requirement.

Illinois: Two-Tier NP System

The Framework: Illinois allows telehealth broadly with no state restrictions on controlled substance prescribing beyond federal law. All prescribers need an Illinois Controlled Substance License in addition to their professional license and DEA registration.

For Nurse Practitioners — Two Pathways:

1. Under Collaboration (Standard NPs):

• Require written collaborative agreement with physician
• Can prescribe Schedule II for 30-day supply only
• Any continuation beyond 30 days requires physician approval
• Physician must review NP’s Schedule II prescribing monthly

2. Full Practice Authority (Experienced NPs):

• Available after 4,000 clinical hours + 250 CE hours
• Can prescribe independently, including stimulants
• No physician consultation required for non-narcotic Schedule IIs like amphetamines
• (Note: Opioids and benzos still require physician consultation even with FPA)

This is a significant distinction. An Illinois PMHNP with Full Practice Authority can prescribe ADHD medications entirely independently via telehealth.

Key Requirements:

• Illinois license plus Illinois Controlled Substance License
• PDMP check recommended for all controlled substances (legally mandated for opioids/benzos)
• Electronic prescribing required

Bottom Line: Illinois offers a clear path to independent NP practice for experienced providers, which is excellent for telehealth scalability. Newer NPs need physician collaboration and face the same 30-day limit as Pennsylvania.

Comparison Table: State Requirements at a Glance

What This Means for Your Practice

If You’re a Psychiatrist

You have the most straightforward path. In every state, you can:

• Diagnose and treat ADHD via telehealth
• Prescribe Schedule II stimulants after appropriate video evaluation
• Manage patients long-term without in-person requirements (during current federal flexibility)

Your main compliance tasks:

• Maintain proper clinical documentation
• Check state PDMPs as required
• Use electronic prescribing
• Ensure you’re licensed in the patient’s state
• Stay current on DEA rule changes expected in 2027

Economic reality: Building your own patient pipeline through SEO, Google Ads, or directory listings typically costs $200-500+ per acquired patient when you factor in all costs — agency fees, ad testing, staff time qualifying leads, no-shows from cold leads, and the 6-12 month SEO ramp-up. Most solo psychiatrists don’t have the marketing budget or patience for this.

Platforms like Klarity offer an alternative: pay only when you see patients (similar to Zocdoc’s model), with pre-qualified patients already matched to your specialty and availability. No upfront marketing spend, no wasted ad budget, no separate EHR costs. You control your schedule and only pay a standard listing fee per new patient lead — guaranteed ROI instead of gambling on marketing channels.

If You’re a Psychiatric Nurse Practitioner

Your authority varies significantly by state:

Full Independence (CA by 2026, NY after 3,600 hrs, IL with FPA): You can build an entirely independent telehealth ADHD practice, prescribing stimulants without physician oversight.

Collaborative Practice (PA, FL, IL without FPA): You can manage ADHD patients but need physician involvement for prescribing. In PA and IL, you’re limited to 30-day initial prescriptions. In Florida, you need a protocol with a psychiatrist.

Restricted Practice (TX): You cannot prescribe ADHD stimulants in outpatient settings. A physician must write all stimulant prescriptions.

Strategic consideration: If you’re in a restrictive state but licensed (or willing to get licensed) in a full-practice-authority state, telehealth platforms can connect you with patients in those more permissive jurisdictions. This dramatically expands your market without requiring you to relocate.

The same economic reality applies: acquiring your own patients is expensive and uncertain. A pay-per-appointment model eliminates that risk entirely, especially valuable if you’re building experience hours toward FPA or don’t have capital for a 6-month marketing investment.

The Economics of Telehealth ADHD Practice

Let’s be direct about patient acquisition costs, because this is where most providers underestimate the real investment:

DIY Marketing Reality:

• Google Ads: Mental health keywords cost $15-40+ per click. Most clicks don’t convert. Realistic cost per booked patient: $200-400+
• SEO: Takes 6-12 months of consistent investment before generating meaningful patient flow
• Psychology Today/Zocdoc: Monthly fees ($30-350+) plus you’re competing with hundreds of providers on the same page
• Full-service marketing: Expect $3,000-5,000/month for a comprehensive campaign (SEO + PPC + content), with no guaranteed results

Total true cost when you factor in agency fees, testing and optimization, staff time handling leads, no-show rates from cold leads, and months before results: Most providers spend $200-500+ per acquired psychiatric patient.

The Platform Alternative:

Klarity Health uses a pay-per-appointment model where you pay a standard listing fee only when a qualified patient books with you. The value proposition:

• No upfront spend: No monthly marketing retainers or ad budget
• Pre-qualified patients: Already matched to your specialty, availability, and insurance/cash-pay preference
• No wasted budget: Every dollar goes toward an actual appointment, not clicks that don’t convert
• Built-in infrastructure: Telehealth platform, EHR, billing support included (no separate $100-300/month platform fees)
• Both insurance and cash-pay: Access to diverse patient populations
• You control your schedule: Set your availability, accept only patients you want to see

The math: Instead of spending $3,000-5,000/month on uncertain marketing results, you pay only when patients show up. That’s guaranteed ROI.

This model makes particular sense for:

• Providers starting telehealth without established patient flow
• Experienced clinicians expanding into new states
• Anyone who’d rather spend time treating patients than managing marketing agencies

Practical Compliance Checklist

Regardless of your state, here’s what you need to practice telehealth ADHD care legally:

Licensure:

• [ ] Active, unrestricted license in patient’s state
• [ ] DEA registration covering that state
• [ ] State-specific controlled substance license if required (IL, NY)

Technology:

• [ ] HIPAA-compliant video platform
• [ ] Electronic prescribing capability (EPCS certified for controlled substances)
• [ ] Secure documentation system

Clinical Process:

• [ ] Proper ADHD evaluation via live video (not just questionnaire)
• [ ] Documented diagnostic criteria and clinical reasoning
• [ ] Patient identity verification
• [ ] Informed consent for telehealth

PDMP Compliance:

• [ ] Access to state PDMP system
• [ ] Protocol for checking before prescribing (frequency varies by state)
• [ ] Documentation of PDMP review in patient record

Ongoing Requirements:

• [ ] Professional liability insurance covering telehealth
• [ ] Understanding of state-specific quantity limits or approval requirements
• [ ] System to track DEA rule changes (especially as 2026 deadline approaches)

What to Watch: 2026-2027 Regulatory Changes

The current federal flexibility expires December 31, 2026. Here’s what to monitor:

DEA Rule Finalization: The three proposed rules announced in January 2025 should be finalized and published in the Federal Register during 2026. These will establish:

• The telemedicine special registration process
• Specific PDMP and identity verification requirements
• Platform registration requirements

State Responses: Some states may adjust their laws in response to new federal rules. New York’s May 2025 update shows how states are aligning with federal changes.

Practice Impact: Most experts expect the final rules will preserve telehealth access for ADHD treatment while adding safeguards. The special registration will likely become the standard way to prescribe controlled substances via telehealth long-term.

Your action item: Don’t wait until December 2026. Start preparing now by ensuring your clinical documentation is thorough, your PDMP checking is consistent, and you’re familiar with the proposed requirements. When the special registration becomes available, apply early.

Common Questions Answered

Q: Can I do an audio-only consult for ADHD medication management?

Not for initial prescriptions. Federal guidance and most state telehealth laws require live two-way audiovisual communication (video) for prescribing controlled substances. Audio-only exceptions exist for buprenorphine in some cases, but not for ADHD stimulants.

Q: Do I need to see ADHD patients in person eventually?

Currently, no — the federal extension through 2026 eliminates the in-person requirement entirely. The proposed permanent rules suggest an ‘established patient’ exception (one in-person visit creates ongoing telehealth authorization), but it’s not yet required. Clinical judgment should guide whether an in-person visit is necessary for any individual patient.

Q: What if my patient travels to another state?

You can only prescribe when the patient is physically located in a state where you hold an active license. If your patient travels, they either need to wait until they return, or you need to be licensed in that state. Some platforms help providers obtain multi-state licensure for this reason.

Q: Are there differences in prescribing for pediatric vs adult ADHD?

The prescribing rules are generally the same, but you need parental/guardian consent for minors, and some states require the parent to be present during telehealth visits for children. Florida has specific requirements for psychiatric medications in minors (consulting pediatrician or psychiatrist). Clinical evaluation standards differ (you need appropriate pediatric training and tools), but the legal framework for controlled substance prescribing is the same.

Q: Can I prescribe 90-day supplies via telehealth?

This varies by state. New York explicitly allows 90-day stimulant prescriptions for ADHD when coded properly. Most other states default to 30-day limits for Schedule II substances. Check your state’s controlled substance regulations — and remember that NPs in PA and IL (without FPA) are limited to 30-day initial prescriptions regardless.

Q: What documentation do I need to prove compliance?

At minimum: informed consent for telehealth, clinical evaluation notes supporting ADHD diagnosis, documentation of PDMP check, patient identity verification, and medication monitoring plan. Treat your telehealth documentation exactly as you would in-person notes — the standard of care is identical.

The Bottom Line for Providers

Yes, you can prescribe ADHD medications via telehealth in 2026. The federal extension through December 31, 2026 provides clear authorization, and most states have aligned their rules to support psychiatric telehealth.

But success requires:

• Understanding your specific state’s requirements
• Maintaining rigorous clinical documentation
• Staying current on regulatory changes
• Having the right technology infrastructure
• Managing PDMP compliance

The bigger question isn’t whether it’s legal — it’s whether you want to build and market your own telehealth practice or join a platform that handles patient acquisition, compliance infrastructure, and administrative burden.

If you’re spending more time figuring out Google Ads than treating patients, there’s a better way. Platforms like Klarity remove the marketing risk entirely: you see patients, you get paid, and someone else handles everything else. No upfront investment, no wasted ad spend, no 6-month wait for SEO results.

Ready to explore telehealth ADHD practice? Join Klarity’s provider network to access pre-qualified patients, built-in compliance support, and a pay-per-appointment model that eliminates financial risk. Set your own schedule, choose your states, and focus on what you do best — treating patients.

Apply to join Klarity’s provider network →

Sources and Citations

All regulatory information in this guide has been verified against official sources current as of February 2026:

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026) – Official announcement of fourth telehealth flexibility extension through December 31, 2026. HHS.gov

2. DEA Press Release – Three New Telemedicine Rules (January 16, 2025) – Official summary of proposed permanent rules including special registration, PDMP requirements, and platform oversight. DEA.gov

3. New York State Department of Health – Bureau of Narcotic Enforcement Guidance on Prescribing Controlled Substances via Telehealth (May 21, 2025) – Official guidance aligning New York regulations with federal telehealth allowances. Ninth District Medical Society

4. Florida Statutes §456.47 – Telehealth provisions including psychiatric disorder exception for Schedule II prescribing. Current through 2025 session. Florida Legislature

5. Texas Board of Nursing – APRN Practice FAQ on Schedule II prescribing limitations. Current as of 2025. Texas Board of Nursing

Additional state regulations, PDMP requirements, and scope of practice details verified through official state medical board and nursing board sources, state statutes, and administrative codes current through February 2026.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care